百奧賽圖-B(02315.HK)：DeepSeek平臺本地化部署及"千鼠萬抗"抗體藥物研發戰略升級
格隆匯2月28日丨百奧賽圖-B(02315.HK)宣佈，公司近期已完成人工智能("AI")驅動抗體藥物研發平臺深度求索(以下簡稱"DeepSeek")的本地化部署，並實現其與本公司核心業務「千鼠萬抗」計劃的全面協同。此次技術整合標誌着抗體藥物早期研發領域邁向智能化和數據化的新階段，未來將爲全球藥企提供更精準及更具突破性的抗體藥物研發方案，大大加速藥物研發進程。
百奧賽圖於2020年啓動「千鼠萬抗」計劃，針對1,000+潛在的抗體藥物靶點，分別在自主開發的RenMab、RenLite及RenNano等全人抗體小鼠平臺上進行抗體研發。目前已獲得針對1,000+藥物靶點的50萬+的全人抗體序列分子，涵蓋單抗、雙抗及納米抗體等各種抗體分子形式，兼具高親和力、低免疫原性及成藥性優勢，未來該全人抗體分子庫將快速提升至千萬級別。
百奧賽圖深刻認識到A I在抗體藥物研發中的巨大潛力，因此率先本地化部署DeepSeek平臺。結合DeepSeek平臺，AI算法可對「千鼠萬抗」的海量真實抗體分子庫實現關鍵賦能，從而避免了常見的「AI幻覺」。
百奧賽圖通過「千鼠萬抗」抗體分子庫和DeepSeek平臺的結合，可爲全球藥企提供全新的單抗、雙抗和多抗分子骨架。這些分子骨架具有高親和力、低免疫原性和優異的成藥性。藉助DeepSeek平臺，全球藥企可以從「千鼠萬抗」真實存在的千萬級別抗體分子庫中，快速篩選出具有極高成藥潛力的目標抗體分子。DeepSeek還可以通過模擬分子相互作用，藉助「千鼠萬抗」龐大抗體分子庫篩選獲得分子骨架，快速設計出具有特定功能的多特異性抗體，如雙抗和多抗等，快速開發出針對各種疾病的創新抗體藥物，大大加速藥物研發進程，滿足未被滿足的臨牀需求。
未來，隨着「千鼠萬抗」和DeepSeek的深度融合，百奧賽圖將爲全球藥企提供更加高效的研發工具和更爲豐富的抗體分子庫，推動抗體藥物的快速發展。隨着AI技術的進一步發展和應用，抗體藥物研發將迎來革命性的變革。百奧賽圖將繼續深耕這創新領域，攜手全球合作夥伴，共同爲全球患者帶來更多高效、安全的治療選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
